Trial Profile
Comparison of the efficacy and safety of zotarolimus [Endeavor]-eluting stent versus sirolimus [Cypher]-eluting stent versus paclitaxel [Taxus]-eluting stent for acute myocardial infarction patients
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Sirolimus (Primary) ; Zotarolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Myocardial infarction
- Focus Adverse reactions
- Acronyms ZEST-AMI
- 23 Feb 2011 Planned number of patients changed from 1500 to NULL.
- 15 Nov 2009 Results have been published (American Journal of Cardiology 104: 1370-1376, No. 10, 15 Nov 2009.)
- 31 Oct 2008 Results have been reported in a Cordis media release.